Effects of pupil dilation with topical 0.5% tropicamide on retinal vascular parameters assessed by VAMPIRE® software in healthy cats.
Cat
Fundus oculi
Retinal imaging analysis
Retinal vessels
Tropicamide
VAMPIRE®
Journal
Research in veterinary science
ISSN: 1532-2661
Titre abrégé: Res Vet Sci
Pays: England
ID NLM: 0401300
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
08
03
2023
revised:
09
05
2023
accepted:
16
05
2023
medline:
12
6
2023
pubmed:
3
6
2023
entrez:
2
6
2023
Statut:
ppublish
Résumé
Our study investigates the effects of mydriasis obtained with topical 0.5% tropicamide on retinal vascular parameters evaluated in cats using the retinal imaging software: Vascular Assessment and Measurement Platform for Images of the Retina (VAMPIRE®). Forty client-owned healthy adult cats were included in the study. Topical 0.5% tropicamide was applied to dilate only the right pupil. The left eye was used as a control. Before dilation (T0), infrared pupillometry of both pupils was performed and fundus oculi images were taken from both eyes. Right eye fundus images were then captured 30 min after topical application of tropicamide (T30), when mydriasis was achieved. The retinal vessel widths (3 arteries and 3 veins) were measured with VAMPIRE® in four standard measurement areas (SMA) identified with the letters A, B, C, D. Average value of the 3 vessel widths was used. After normality assessment, the t-test was used to analyse the mean difference in vascular parameters of the left and right eyes at T0 and T30, with p set <0.05. The two eyes showed no statistical differences in pupil and vascular parameter measurements at T0. At T30, only one artery measurement of the right eye (SMA A-peripapillary area) showed a small but statistically significant mean vasoconstriction of approximately 4%. The results indicate that local application of 0.5% tropicamide seems to be associated with a small retinal arteriolar vasoconstriction as assessed by VAMPIRE® in cats. However, this change is minimal, and should not affect the interpretation of the results when VAMPIRE® is used.
Identifiants
pubmed: 37267768
pii: S0034-5288(23)00140-6
doi: 10.1016/j.rvsc.2023.05.008
pii:
doi:
Substances chimiques
Tropicamide
N0A3Z5XTC6
Mydriatics
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
50-54Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.